Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7276
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma ; volume:30 ; number:7 ; day:15 ; month:5 ; year:2013 ; pages:867-876 ; date:10.2013
Clinical & experimental metastasis ; 30, Heft 7 (15.5.2013), 867-876, 10.2013
- Urheber
-
Birkeland, Einar
Busch, Christian
Berge, Elisabet Ognedal
Geisler, Jürgen
Jönsson, Göran
Lillehaug, Johan Richard
Knappskog, Stian
Lønning, Per Eystein
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10585-013-9587-4
- URN
-
urn:nbn:de:101:1-2019062921001224210069
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Birkeland, Einar
- Busch, Christian
- Berge, Elisabet Ognedal
- Geisler, Jürgen
- Jönsson, Göran
- Lillehaug, Johan Richard
- Knappskog, Stian
- Lønning, Per Eystein
- SpringerLink (Online service)
Ähnliche Objekte (12)
MEK targeting in N-RAS mutated metastatic melanoma
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Clinical significance of BRAF mutations in metastatic melanoma
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma
Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen
Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations
HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy
MEK targeting in N-RAS mutated metastatic melanoma
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Clinical significance of BRAF mutations in metastatic melanoma
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma
Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen
Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations
HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy
MEK targeting in N-RAS mutated metastatic melanoma
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Clinical significance of BRAF mutations in metastatic melanoma
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma
Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen
Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations